Clinical trials and real-world analyses have consistently demonstrated the positive impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on cardiorenal outcomes in patients with type 2 diabetes (T2D), heart failure (HF), and chronic kidney disease (CKD). As a result, SGLT2 inhibitors have acquired a central role in the treatment of T2D, CKD, and HF.
This educational activity will present the latest data from landmark clinical trials examining the effects of SGLT2 inhibitors on cardiorenal outcomes. Our expert faculty will review updated clinical practice guidelines for heart failure, diabetes, and CKD, and describe care models that incorporate pharmacists into the initiation, titration, and monitoring of SGLT2 inhibitor therapy for patients who could benefit from treatment.
Join us Monday, Dec. 4, from 11:30 a.m. to 1 p.m. PT, for the Midday Symposium Challenges in Cardiometabolic Care: Interprofessional Implementation of SGLT2 Inhibitors, held in room 159, 100 Level, Anaheim Convention Center North. Earn 1.5 hours of CE credit.
The Midday Symposium will also be broadcast as a live webinar for CE credit. If you have colleagues at home who are interested in this topic, encourage them to register for the webinar.
This activity is provided by ASHP and supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.
